Status:
NOT_YET_RECRUITING
AI-driven Clinical Decision Support to Reduce Hospital-Acquired Venous Thromboembolism: Study Protocol for the VTE-AI Randomized Trial.
Lead Sponsor:
Vanderbilt University Medical Center
Conditions:
Venothromboembolism
Eligibility:
All Genders
Phase:
NA
Brief Summary
Hospital-acquired blood clots (HA-VTE) are the leading cause of death in hospitalized patients in the US. Each year, about 900,000 people get blood clots, costing between $7 and $10 billion in medical...
Detailed Description
Background Hospital Acquired Venous Thromboembolism (HA-VTE) remains the leading cause of death in hospitalized patients in the US. Approximately 900,000 people experience VTE each year, with incidenc...
Eligibility Criteria
Inclusion
- Inpatient admission to Vanderbilt Adult Hospital, Vanderbilt Tullahoma Harton Hospital, Vanderbilt Bedford County Hospital, or Vanderbilt Wilson County Hospital
Exclusion
- None
Key Trial Info
Start Date :
December 17 2025
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
March 31 2027
Estimated Enrollment :
2236 Patients enrolled
Trial Details
Trial ID
NCT06939803
Start Date
December 17 2025
End Date
March 31 2027
Last Update
December 10 2025
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.